Enavate Sciences GP, LLC
Enavate Sciences GP, LLC's purchase track record
Enavate Sciences GP, LLC has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/15/2024 | CAMP | $15.00M | -65.2% | -82.8% | -7.2% |
| 9/16/2024 | ZBIO | $15.00M | -51.2% | -53.1% | +0.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.
Transaction History
| CAMP | ▼ Sell | Other | 2,422,166 | — | 10/15/2024 | View on chart |
| CAMP | ▲ Buy | Open Market | 1,363,636 | $15.0M | 10/15/2024 | View on chart |
| ZBIO | ▼ Sell | Other | 2,879,006 | — | 9/16/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 882,353 | $15.0M | 9/16/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial
CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial. CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.